Abstract | BACKGROUND: METHODS: RESULTS: Treatment resulted in significant reductions in LDL cholesterol levels of 41 +/- 22 percent in the LDL-lowering- antioxidant group and 38 +/- 20 percent in the LDL-lowering group (P < 0.001 vs. the diet group). The maximal changes in coronary-artery diameter with acetylcholine at base line and at follow-up were -19 and -2 percent, respectively, in the LDL-lowering- antioxidant group, -15 and -6 percent in the LDL-lowering group, and -14 and -19 percent in the diet group (P < 0.01 for the LDL-lowering- antioxidant group vs. the diet group; P = 0.08 for the LDL-lowering group vs. the diet group). (The negative numbers indicate vasoconstriction). Thus, the greatest improvement in the vasoconstrictor response was seen in the LDL-lowering- antioxidant group. CONCLUSIONS:
|
Authors | T J Anderson, I T Meredith, A C Yeung, B Frei, A P Selwyn, P Ganz |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 332
Issue 8
Pg. 488-93
(Feb 23 1995)
ISSN: 0028-4793 [Print] United States |
PMID | 7830729
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anticholesteremic Agents
- Antioxidants
- Cholestyramine Resin
- Lovastatin
- Acetylcholine
- Probucol
|
Topics |
- Acetylcholine
(therapeutic use)
- Anticholesteremic Agents
(therapeutic use)
- Antioxidants
(therapeutic use)
- Cholestyramine Resin
(therapeutic use)
- Coronary Artery Disease
(drug therapy, physiopathology)
- Endothelium, Vascular
(drug effects, physiopathology)
- Female
- Follow-Up Studies
- Humans
- Hypercholesterolemia
(drug therapy)
- Lovastatin
(therapeutic use)
- Male
- Middle Aged
- Probucol
(therapeutic use)
- Regression Analysis
- Vasoconstriction
(drug effects)
- Vasodilation
(drug effects)
|